TEL AVIV, Israel and BETHESDA, Maryland, Nov. 1, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced their CEO, Eyal Barad, will speak on a panel at the Marijuana Business Conference (MJBizCon) held in Las Vegas. MJBizCon 2018 is the flagship event of MJBizDaily and one of the preeminent conferences helping to drive business deals and forge valuable connections with cannabis professionals in the sector.
At the conference, Mr. Barad will join thought leaders in the space on November 13th during “The Business of Hemp Forum” from 2:30 p.m. – 3:00 p.m. PT. He will touch on the studies underway at Cannabics to treat cancer with cannabinoids through the use of big data and artificial intelligence, while offering examples of how Cannabics has positioned itself as a leader in cannabinoid research through strategic decisions and partnerships, such as their recent collaboration with Seedo. Mr. Barad also plans to share insights during the discussion of how legislation in Canada and the United States create the opportunity for changes in the medical cannabis community and research needs, leaning into his extensive media and economics background to inform the topic.
“This conference brings together some of the most innovative minds working in cannabis today,” said Eyal Barad. “I’m greatly looking forward to experience. The goal of our attendance and panel participation is to empower and inspire those in the industry, while spurring questions that will continue to propel us forward in our continued work in this emerging space.”
In addition to attending sessions, Mr. Barad will be connecting with scientific and research institutes interested in learning more about the research and studies currently underway at Cannabics.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.